Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Forecast Highlights Expansion From $2.1 Billion To $5.95 Billion Through 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for AI-powered platforms designed to identify patients with rare diseases has experienced significant expansion. Projections indicate a substantial increase from $1.62 billion in 2025 to $2.11 billion in 2026, reflecting a compound annual growth rate of 29.9%. This upward trajectory in the historical period stems from several key factors, including the greater accessibility of electronic health records, the early integration of data analytics into clinical research endeavors, the broadening scope of genomic databases, a heightened emphasis on orphan diseases, and the nascent application of artificial intelligence in facilitating clinical trial recruitment.
The market for AI-powered rare disease patient identification is projected for significant expansion soon, reaching an estimated $5.95 billion by 2030 with a compound annual growth rate (CAGR) of 29.6%. Factors propelling this growth include heightened investment in precision medicine initiatives, a greater need for accelerated clinical trial participant recruitment, the broadened application of real-world evidence analysis, augmented partnerships between healthcare and life sciences organizations, and increased governmental backing for rare disease advancements. Key developments anticipated during this period involve greater adoption of AI algorithms for pinpointing patients, more comprehensive integration of diverse health data sources, enhanced automation in clinical trial recruitment processes, the proliferation of precision patient matching services, and a strengthened commitment to facilitating rare disease research.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Expansion Drivers: What Is Shaping Future Growth?
The expansion of artificial intelligence (AI) powered tools for identifying patients with rare diseases is anticipated to be significantly boosted by the growing adoption of digital health and telemedicine. These technologies, encompassing a range of electronic tools, software, and devices for health monitoring and management, along with remote healthcare delivery through telecommunication means like video conferencing and mobile applications, are becoming increasingly favored. This heightened interest stems from both patients and healthcare professionals looking for more accessible, efficient, and time-conscious healthcare options. AI systems designed to find rare disease patients play a crucial role in supporting these digital and remote healthcare approaches by precisely pinpointing individuals, facilitating remote patient observation, enabling prompt virtual medical appointments, and offering tailored treatment plans. Supporting these advancements, a report from the Organisation for Economic Co operation and Development in November 2025 indicated that member nations have advanced their efforts in broadening access to electronic health records (EHRs). Furthermore, in 2024, the average availability of online digital health services across countries with comparable data stood at 82%, a rise from 79% observed in 2023. Consequently, the escalating embrace of digital health and telemedicine is a key factor fueling the market growth for AI-driven rare disease patient finder solutions.
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Segment Landscape: Which Areas Lead Market Development?
The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –
1) By Component: Software, Services
2) By Deployment Mode: Cloud-Based, On-Premises
3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications
4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users
Subsegments:
1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System
2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Strategic Trends: What Is Defining The Next Phase Of Growth?
In the landscape of the AI-driven rare disease patient finder market, leading entities are prioritizing the creation of innovative technological solutions, such as precision patient recruitment platforms. These advancements aim to bolster the precision, rapidity, and effectiveness of pinpointing suitable candidates for rare disease clinical studies. The ultimate goal is to shorten enrollment periods and elevate the likelihood of trial success. A precision patient recruitment solution represents a sophisticated, technology-enabled strategy that leverages sophisticated algorithms alongside real-world data to precisely locate and connect with individuals who align with the precise inclusion and exclusion criteria of a given clinical trial. As a case in point, in April 2024, Citeline, an American enterprise renowned for its business intelligence and data analytics capabilities, introduced its Citeline PatientMatch platform. This innovative tool integrates cutting-edge algorithms with an extensive repository of real-world data, encompassing laboratory results, biomarker information, and electronic health records sourced from more than 400 healthcare institutions. Its purpose is to empower both trial sponsors and researchers by facilitating the prompt and effective identification of eligible participants, thereby optimizing the enrollment process and accommodating intricate and varied study designs across a spectrum of medical disciplines.
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Industry Leaders And Market Competition
Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.
Access The Complete Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Regional Analysis And Leading Geography
North Americawas the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
